Akebia Therapeutics, Inc. - Common Stock (AKBA)

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / Common Stock
Shares outstanding
266,941,931
Total 13F shares
56,991,509
Share change
+914,077
Total reported value
$104,293,412
Put/Call ratio
80%
Price per share
$1.83
Number of holders
108
Value change
+$2,027,480
Number of buys
61
Number of sells
36

Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2024

As of 31 Mar 2024, Akebia Therapeutics, Inc. - Common Stock (AKBA) was held by 108 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 56,991,509 shares. The largest 10 holders included Alerce Investment Management, L.P., VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, BlackRock Inc., Qube Research & Technologies Ltd, GEODE CAPITAL MANAGEMENT, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, and JACOBS LEVY EQUITY MANAGEMENT, INC. This page lists 108 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.